Phenotypic and molecular analyses of primary lateral sclerosis

Neurology: Genetics

Volumn 1, Issue 1, 2015, Pages

  Mitsumoto, Hiroshi ^a   Nagy, Peter L ^a,b   Gennings, Chris ^c   Murphy, Jennifer ^d   Andrews, Howard ^a   Goetz, Raymond ^a   Floeter, Mary Kay ^e   Hupf, Jonathan ^a   Singleton, Jessica ^a   Barohn, Richard J ^f   Nations, Sharon ^g   Shoesmith, Christen ^h   Kasarskis, Edward ⁱ   Factor Litvak, Pam ^j  

^a NewYork Presbyterian Hospital   (United States)

^b CUMC   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^f UNIVERSITY OF KANSAS   (United States)

^g UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^h UNIVERSITY OF WESTERN ONTARIO   (Canada)

ⁱ UNIVERSITY OF KENTUCKY   (United States)

^j NONE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; C9ORF72 GENE; CLINICAL ARTICLE; CLINICAL FEATURE; COGNITION; DCTN1 GENE; DEMOGRAPHY; EXOME; FEMALE; GENE; GENE SEQUENCE; GENETIC MARKER; HUMAN; MALE; MIDDLE AGED; MULTICENTER STUDY; PARK2 GENE; PHENOTYPE; PRIMARY LATERAL SCLEROSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; SECONDARY ANALYSIS; SPG7 GENE;

EID: 85046981879     PISSN: None     EISSN: 23767839     Source Type: Journal    
DOI: 10.1212/01.NXG.0000464294.88607.dd     Document Type: Article

References (38)

1. Le Forestier N, Maisonobe T, Spelle L, et al. Primary lateral sclerosis: further clarification. J Neurol Sci 2001;185:95-100.
2. D'Amico E, Pasmantier M, Lee YW, Weimer L, Mitsumoto H. Clinical evolution of pure upper motor neuron disease/dysfunction (PUMMD). Muscle Nerve 2013;47:28-32.
3. Gordon PH, Cheng B, Katz IB, Mitsumoto H, Rowland LP. Clinical features that distinguish PLS, upper motor neuron-dominant ALS, and typical ALS. Neurology 2009;72:1948-1952.
4. Pringle CE, Hudson AJ, Munoz DG, Kiernan JA, Brown WF, Ebers GC. Primary lateral sclerosis - clinical features, neuropathology and diagnostic criteria. Brain 1992;115:495-520.
5. Tartaglia MC, Rowe A, Findlater K, Orange JB, Grace G, Strong MJ. Differentiation between primary lateral sclerosis and amyotrophic lateral sclerosis-examination of symptoms and signs at disease onset and during follow-up. Arch Neurol 2007;64:232-236.
6. Le Forestier N, Maisonobe T, Piquard A, et al. Does primary lateral sclerosis exist? A study of 20 patients and a review of the literature. Brain 2001;124:1989-1999.
7. Zhai P, Pagan F, Statland J, Butman JA, Floeter MK. Primary lateral sclerosis: a heterogeneous disorder composed of different subtypes? Neurology 2003;60:1258-1265.
8. Mitsumoto H, Factor-Litvak P, Andrews H, et al. ALS Multicenter Cohort Study of Oxidative Stress (ALS COSMOS): study methodology, recruitment, and baseline demographic and disease characteristics. Amyotroph Lateral Scler Frontotemporal Degener 2014;15:192-203.
9. Chan S, Kaufmann P, Shungu DC, Mitsumoto H. Amyotrophic lateral sclerosis and primary lateral sclerosis: evidence-based diagnostic evaluation of the upper motor neuron. Neuroimaging Clin N Am 2003;13:307-326.
10. Brugman F, Veldink JH, Franssen H, et al. Differentiation of hereditary spastic paraparesis from primary lateral sclerosis in sporadic adult-onset upper motor neuron syndromes. Arch Neurol 2009;66:509-514.
11. Lezak MD. Neurological Assessment. New York: Oxford University Press; 2004.
12. Tanioka K, Tadohisa H. Effect of data standardization on the result of k-means clustering. In: Wolfgang G, Geyer-Schulz A, Schmidt-Thieme L, Kunze J, editors. Challenges at the Interface of Data Analysis, Computer Science, and Optimization, Studies in Classification, Data Analysis, and Knowledge Organization. Berlin: Springer; 2012:59-67.
13. Tibshirani R. Regression shrinkage and selection via the Lasso. J Roy Stat Soc B Met 1996;58:267-288.
14. Renton AE, Majounie E, Waite A, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 2011;72:257-268.
15. Chin EL, da Silva C, Hegde M. Assessment of clinical analytical sensitivity and specificity of next-generation sequencing for detection of simple and complex mutations. BMC Genet 2013;14:6.
16. Landrum MJ, Lee JM, Riley GR, et al. ClinVar: public archive of relationships among sequence variation and human phenotype. Nucleic Acids Res 2014;42: D980-D985.
17. 1000 Genomes Project Consortium, Abecasis GR, Altschuler D, et al. A map of human genome variation from population-scale sequencing. Nature 2010;467:1061-1073.
18. Krumm N, Sudmant PH, Ko A, et al. Copy number variation detection and genotyping from exome sequence data. Genome Res 2012;22:1525-1532.
19. Luu TD, Rusu AM, Walter V, et al. MSV3d: database of human MisSense variants mapped to 3D protein structure. Database (Oxford) 2012:bas018.
20. Choi Y, Sims GE, Murphy S, Miller JR, Chan A. Predicting the functional effect of amino acid substitutions and indels. PLoS One 2012;7:e46688.
21. Roxburgh RH, Marquis-Nicholson R, Ashton F, et al. The p.Ala510Val mutation in the SPG7 (paraplegin) gene is the most common mutation causing adult onset neurogenetic disease in patients of British ancestry. J Neurol 2013;260:1286-1294.
22. Cookson MR, Lockhart PJ, McLendon C, O'Farrell C, Schlossmacher M, Farrer MJ. RING finger 1 mutations in Parkin produce altered localization of the protein. Hum Mol Genet 2003;12:2957-2965.
23. Münch C, Sedlmeier R, Meyer T, et al. Point mutations of the p150 subunit of dynactin (DCTN1) gene in ALS. Neurology 2004;63:724-726.
24. Zhang QP, Bethmann C, Worth NF, et al. Nesprin-1 and -2 are involved in the pathogenesis of Emery Dreifuss muscular dystrophy and are critical for nuclear envelope integrity. Hum Mol Genet 2007;16:2816-2833.
25. Zou H, Hastie T. Regularization and variable selection via the elastic net. J Roy Stat Soc B 2005;67:301-320.
26. Klebe S, Depienne C, Gerber S, et al. Spastic paraplegia gene 7 in patients with spasticity and/or optic neuropathy. Brain 2012;135:2980-2993.
27. Sanchez-Ferrero E, Coto E, Beetz C, et al. SPG7 mutational screening in spastic paraplegia patients supports a dominant effect for some mutations and a pathogenic role for p.A510V. Clin Genet 2013;83:257-262.
28. van Rheenen W, van Blitterswijk M, Huisman MH, et al. Hexanucleotide repeat expansions in C9ORF72 in the spectrum of motor neuron diseases. Neurology 2012;79:878-882.
29. Cooper-Knock J, Shaw PJ, Kirby J. The widening spectrum of C9ORF72-related disease; genotype/phenotype correlations and potential modifiers of clinical phenotype. Acta Neuropathol 2014;127:333-345.
30. Gilbert RM, Fahn S, Mitsumoto H, Rowland LP. Parkinsonism and motor neuron diseases: twenty-seven patients with diverse overlap syndromes. Mov Disord 2010;25:1868-1875.
31. Norlinah IM, Bhatia KP, Ostergaard K, Howard R, Arabia G, Quinn NP. Primary lateral sclerosis mimicking atypical parkinsonism. Mov Disord 2007;22:2057-2062.
32. Sun M, Latourelle JC, Wooten GF, et al. Influence of heterozygosity for Parkin mutation on onset age in familial Parkinson disease: the GenePD study. Arch Neurol 2006;63:826-832.
33. Farrer M, Chan P, Chen R, et al. Lewy bodies and parkinsonism in families with parkin mutations. Ann Neurol 2001;50:293-300.
34. Klein C, Lohmann-Hedrich K, Rogaeva E, Schlossmacher MG, Lang AE. Deciphering the role of heterozygous mutations in genes associated with parkinsonism. Lancet Neurol 2007;6:652-662.
35. Nichols WC, Marek DK, Pauciulo MW, et al. R1514Q substitution in Lrrk2 is not a pathogenic Parkinson's disease mutation. Mov Disord 2007;22:254-257.
36. Anfossi M, Colao R, Gallo M, et al. Identification of three novel LRRK2 mutations associated with Parkinson's disease in a Calabrian population. J Alzheimers Dis 2014;38:351-357.
37. Whittle AJ, Ross OA, Naini A, et al. Pathogenic Lrrk2 substitutions and amyotrophic lateral sclerosis. J Neural Transm 2007;114:327-329.
38. Vilarino-Guell C, Wider C, Soto-Ortolaza AI, et al. Characterization of DCTN1 genetic variability in neurodegeneration. Neurology 2009;72:2024-2028.